As of last Thursday, Rhode Island Medicaid stopped paying for Wegovy and Zepbound when they're prescribed only for weight loss. And there's no grandfathering for the people already on them. This is GLP-1 Daily. Today, Rhode Island becomes at least the seventh state this year to pull Medicaid coverage, Massachusetts shows what happens after the cuts, and Cigna's own employees push back on their employer. Plus a physician's case against the compounding market, and some reassuring data for frailer heart patients on semaglutide. If the show's useful, follow us wherever you're listening. Rhode Island first.
Cole Mercer, writing in Medical Daily:
Rhode Island Medicaid members who take Wegovy, Zepbound, Saxenda, or the new pill Foundayo only for weight loss can no longer get those drugs through the program as of Oct. 1, 2026. In a memo to providers, the state's Executive Office of Health and Human Services (EOHHS) said members using the drugs for weight loss "may no longer be able to obtain them through Medicaid beginning October 1, 2026."
Diabetes prescriptions stay covered. Weight-loss-only prescriptions don't. And the state's spokesperson, Kerri White, said there would be no grandfathering or exemptions for existing patients. The budget math: officials project six point three million dollars in state savings, twenty point three million once federal matching funds are counted. Medicaid paid for twenty-four thousand nine hundred seventy-one obesity GLP-1 prescriptions in fiscal 2025, though that number counts refills and dose changes, not people. Here's the line that stopped me. The state's own budget document said ending coverage could result in health inequities, and it cited obesity rates of thirty-eight and a half percent among Black adults and forty-four point six percent in households earning under fifteen thousand a year. So they wrote down who gets hurt, and then did it anyway. That's not an oversight. That's a decision. Rhode Island Current lists the other six: California, New Hampshire, Pennsylvania, South Carolina, Utah, and Massachusetts. Dr. Amy Nunn of the Rhode Island Public Health Institute put it plainly. The big elephant in the room is the medications are too expensive. Two practical notes. Members under twenty-one still get a medical-necessity review on every prior auth request. And if one of these drugs is medically necessary for something other than weight loss, your prescriber can file a new prior authorization with clinical documentation. If you're affected, talk with your prescriber about other qualifying diagnoses and your appeal rights. Don't stop or switch anything on your own.
Morgan Taylor, writing in The Cool Down:
What happens when insurers stop covering expensive weight-loss drugs? In Massachusetts, use of GLP-1 medications for weight loss dropped 52% between 2025 and the first quarter of 2026, showing how quickly access can change when health plans pull back.
That's a hundred twelve thousand fewer commercially insured people using these drugs for weight loss. The numbers come from the Massachusetts Health Policy Commission, first reported by Worcester Business Journal. Thursday we covered the State House pushback against these cuts. This is the first hard count of what they did. And it happened in one quarter. Blue Cross Blue Shield of Massachusetts went from six point one percent of members using GLP-1s for weight loss at the end of 2025 to three point seven percent in early 2026. Point32 fell from six point five to three point three. Health New England, two point nine to zero point nine. The commission says annualized 2026 spending fell to six hundred sixty-two million dollars. On a spreadsheet, that's the policy working. But where did a hundred twelve thousand people go? Clinicians and patients warned some would pay out of pocket or pause treatment. This data doesn't tell us which. That's the caveat I'd put first. This measures who's filling prescriptions, not anyone's health, and we're reading it secondhand through news coverage of the commission's numbers. And Secretary Kiame Mahaniah is once again predicting a major price crash within two years and a return to full coverage in two to three.
The Obesity Action Coalition, an advocacy group, in a press release:
In June, Cigna notified more than 50,000 U.S. employees that its health plan would stop covering GLP-1 medications for weight management. The decision took effect July 1 and prompted an outpouring of concern from employees. Almost 600 Cigna employees signed a petition asking the company to reinstate coverage.
Cigna is a health company. In the group's words, a company whose work centers on health care and pharmacy benefits. And Bloomberg Businessweek reported one employee went from paying twenty-five dollars a month to about three hundred. Cigna's side, per that same Businessweek reporting: it says the decision was made carefully, based on research and input from leaders across the company, including clinical leaders. It points employees to health coaching and other resources. And it says the decision stands. Health coaching. When the company that designs coverage for millions of other people won't cover its own staff, every HR department in America just got permission. Caveat on the source. This is an advocacy group's release, and nearly six hundred signatures out of more than fifty thousand employees isn't a referendum. But it's open enrollment season. If your employer plan is changing, get the coverage terms in writing and bring them to your prescriber before you make any change to your treatment.
Dr. Adonis Saremi, an obesity medicine physician who runs a virtual practice, in an opinion piece for Fortune:
Federal law lets pharmacies compound for an individual medical need — like an ingredient allergy or an inability to swallow a pill — and to fill temporary gaps during a shortage. When the GLP-1 shortages ended more than a year ago, sellers pivoted: Add a substance, usually vitamin B12, and market the product as personalized. No researcher has studied these combinations in people, and no reasonable person would consider that type of mass workaround a medical necessity.
The regulatory backdrop: the FDA sent a warning letter dated September 18 to Empower Pharmacy, a Houston compounding pharmacy operating under the 503A rules. According to the letter, as summarized by a Florida defense law firm, compounded tirzepatide with niacinamide and semaglutide with B12 were essentially copies of approved drugs, made in inordinate amounts. It also cites insanitary conditions in sterile production, and it flags prescriber notes repeated verbatim across many records, often picked from pre-selected menu options on telehealth platforms. Empower had fifteen working days to respond, and the agency warned seizure and injunction could follow. Those are FDA findings in a warning letter, not a court ruling. Saremi wants the FDA to say outright that cost isn't a medical justification for compounding. Fine. But we just spent three stories on people losing coverage. He admits it himself: these drugs are expensive and coverage is inconsistent. The Rhode Island patient who lost Medicaid on Thursday didn't choose the compounding market. Policy pushed them toward it. And I'll defend some of that market. Compounders filled a real gap during the shortage, and Saremi says some compounding pharmacies are excellent, issuing certificates of analysis and running third-party testing. A pharmacy that tests its product is not the same as a seller you can't trace. If you're on a compounded GLP-1, don't stop or switch on your own. Ask your prescriber and your pharmacist where it's made and how it's tested.
Samantha Anderer, writing in JAMA:
The researchers found that the benefits of semaglutide were consistent across frailty categories, reducing the risk of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke compared with placebo.
This is a secondary analysis of a randomized trial, published in JAMA Cardiology. About seventeen thousand six hundred adults with cardiovascular disease and overweight or obesity. Thirty-one percent were classed as not frail, forty-seven percent more frail, twenty-two percent most frail. Two findings stand out. The quality-of-life benefit was bigger for people who were more frail. And people with higher baseline frailty were less likely to stop the drug because of side effects. Caveat: a secondary analysis isn't what the trial was built to answer, and this JAMA summary doesn't name a funding source. Peer-reviewed, yes. Settled, no. But it matters for exactly the people a doctor might hesitate over. Older, frailer, already carrying heart disease. The researchers' own takeaway: frailty status shouldn't stop people with heart disease and overweight or obesity from considering semaglutide. If someone told you you're too frail for this, that's worth raising with your prescriber.
If you're finding GLP-1 Daily useful, leave us a review wherever you're listening. Reviews help other people find the show, and we really appreciate it.
Links to every story are in the show notes, so dig into whichever ones caught your attention. That's GLP-1 Daily for today. We'll be back tomorrow. This is a Lantern Podcast.